Unafraid of Challenges, Bravely Moving Forward | Hycells Bio Celebrates Its 2nd Anniversary
Release Date:
2023-07-21 13:24
June 30, 2023, marked the mid-year review day for the Hycells Initiative—and coincidentally also the second anniversary of Hycells’s founding. To celebrate this special and meaningful occasion, the team decided to get together a bit early. Two years may seem like but a fleeting moment in the grand sweep of history, yet for Hycells, those two years have been extraordinarily precious and truly unique.
Since its inception, Heyou has grown from scratch to a steadily expanding enterprise. Upholding the core values of talent as the foundation, quality as the priority, and innovation as the driving force, the company has advanced steadily, one step at a time, with unwavering commitment and practicality.
Today, amid a broader domestic economic downturn, the pharmaceutical R&D sector is no exception. While investor caution has slowed momentum, it has not halted the industry’s progress; the current economic chill is prying away the sector’s excesses, and the windfall benefits of rapid growth are gradually fading. Adversity tests the true strength of every individual and every company—after all, challenges can spur rapid development.
Over the past two years, Hycells has focused on personal growth and continuous internal development, steadfastly leveraging technological innovation as the core driver to constantly optimize the technology service platform and streamline operational processes. At the same time, Hycells has deepened compliance governance, advanced the cultivation of a compliance-oriented corporate culture, strengthened internal management mechanisms, and solidified the foundation for the company’s sustainable development.
The photo shows work reports from various departments by Hycells’s colleagues.
The photo captures a leisurely moment after the mid-year report, with some colleagues still deeply engrossed in work.
On the occasion of the second anniversary of HeYou’s founding, we celebrate with joy!
We are deeply grateful for the trust and support of every partner who has stood by us every step of the way!
Thank you to every Hycells team member for your diligent work and unwavering dedication!
The road ahead remains fraught with obstacles—only the brave can prevail!
May we always stay true to our original aspirations, fear no difficulties, and forge ahead with courage!
The photo shows the celebration ceremony for the second anniversary of Hycells.
Related News
HiXpan® Cell Culture Additive: Answers to Key Questions (Part 2)
Hycell’s maximum production capacity per batch is 200–400 units of the 500 mL format, ensuring stable supply and meeting customers’ ongoing production needs.
HiXpan® Cell Culture Additive: Key Questions and Answers (Part 1)
The blood‑derived raw materials used in HiXpan® cell culture additives comply with all regulatory requirements throughout collection, ethical review, informed consent, and commercial authorization, and are supported by a fully traceable supply chain.
This paper focuses on how Hycells transforms biological variability into engineering‑level determinism through a scientifically informed blending strategy and stringent control at the collection end.
(II) Security Assurance Section | Safety First, Defense Prioritized
Compliance‑driven traceability establishes a clear “identity” for the product, but the real test lies in safety. While a multi‑donor pooling strategy ensures batch‑to‑batch consistency, it also inevitably elevates the risk of pathogen introduction. In the face of these associated risks and challenges, Heyousheng has never compromised on its manufacturing standards—relying on more precise design to deliver on its promise of enhanced safety.
This article will examine how Hycells proactively integrates the quality management system into the hospital setting, translating compliance requirements into concrete, actionable practices starting at the sample collection stage, thereby establishing a trust‑based chain that can withstand audit scrutiny.
In selecting hPL raw materials, Heyousheng consistently upholds the principle that “safety is determined at the source.” The samples used in production are rigorously collected in accordance with applicable standards and undergo stringent donor screening, effectively mitigating the risk of disease transmission at the very outset. Moreover, from informed consent forms and ethical approvals to clinical‑grade collection under the GCP framework, Heyousheng has established a fully traceable documentation chain, ensuring that every sample is accounted for and verifiable. In contrast to the industry’s longstanding reliance on the conventional model of using expired blood supplies from blood banks, this approach represents a structural, generational upgrade.
Contact Us
Phone: 021-36696819
Mobile phone:13061948224(Ms. Yu)
Email:monika@hys-bio.com
Wuxi Headquarters: 4th Floor, No. 15-1, Xianfeng Middle Road, Anzhen Subdistrict, Xishan District, Wuxi City
Shanghai Branch: Room 503, Building 2, No. 999 Jiangyue Road, Minhang District, Shanghai
Official Website
WeChat Official Account
Message Board